Vebreltinib Combined With Temozolomide for Glioblastoma (GBM) After Surgery

Inclusion Criteria: 1. Aged 18-65 years, female or male 2. Newly diagnosed GBM (WHO grade 4) patients with maximal surgical resection 3. c-MET overexpression diagnosed by IHC 4. KPS ≥60 5. Adequate hematological, renal, and hepatic function. All patients should meet the following criteria: 1. absolute neutrophil count (ANC) ≥1.5 × 109/L and platelet count≥100 × 109/L 2. serum creatinine clearance ≥80 mL/min 3. total bilirubin level ≤ 1.5 × ULN (except patients with Gilbert syndrome) 4. aspartate aminotransferase (AST) ≤ 3.0 × ULN, alanine aminotransferase (ALT) ≤ 3.0 × ULN, and AST/ALT \< 2.5 × ULN 6. The patient and his/her family members were informed and provided signed and informed consent Exclusion Criteria: 1. Any previous postoperative treatment except for concurrent chemoradiotherapy; 2. Individuals unable to undergo cranial MRI examination; 3. Active hemorrhage detected by cranial CT or MRI scan before enrollment; 4. Uncontrolled hypertension; 5. Decompensated heart failure, unstable angina pectoris, acute myocardial infarction, or persistent and clinically significant arrhythmias within 3 months before enrollment; 6. Anti-HIV (+), or both anti-HCV and HCV-RNA (+), or HBsAg positive with HBV-DNA \>1000IU/ml; 7. Individuals requiring long-term continuous use of hematopoietic growth factors or platelet transfusions; 8. Pregnant or lactating women; 9. Individuals who have received other clinical trial drugs within 30 days before the first dose of the study drug; 10. Individuals deemed unsuitable for participation in this clinical trial by the investigator.